$1.62
1.25% yesterday
Nasdaq, Dec 24, 07:52 pm CET
ISIN
US5560991094
Symbol
MGNX

MacroGenics, Inc. Stock price

$1.62
+0.20 14.08% 1M
+0.28 20.90% 6M
-1.63 50.15% YTD
-1.64 50.31% 1Y
-4.32 72.73% 3Y
-22.68 93.33% 5Y
-29.65 94.82% 10Y
-23.37 93.52% 20Y
Nasdaq, Closing price Wed, Dec 24 2025
+0.02 1.25%
ISIN
US5560991094
Symbol
MGNX
Industry

Key metrics

Basic
Market capitalization
$102.5m
Enterprise Value
$-43.9m
Net debt
positive
Cash
$146.4m
Shares outstanding
63.0m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
0.8 | 0.8
EV/Sales
negative | negative
EV/FCF
0.3
P/B
1.5
Financial Health
Equity Ratio
44.3%
Return on Equity
-57.8%
ROCE
-34.4%
ROIC
-72.8%
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$127.6m | $127.7m
EBITDA
$-70.5m | $-73.4m
EBIT
$-78.0m | $-88.1m
Net Income
$-75.0m | $-77.6m
Free Cash Flow
$-164.3m
Growth (TTM | estimate)
Revenue
-9.7% | -14.9%
EBITDA
29.4% | 28.3%
EBIT
27.3% | 19.9%
Net Income
23.4% | -15.9%
Free Cash Flow
-166.1%
Margin (TTM | estimate)
Gross
75.4%
EBITDA
-55.2% | -57.5%
EBIT
-61.1%
Net
-58.8% | -60.8%
Free Cash Flow
-128.7%
More
EPS
$-1.2
FCF per Share
$-2.6
Short interest
7.0%
Employees
341
Rev per Employee
$440.0k
Show more

Is MacroGenics, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,079 stocks worldwide.

MacroGenics, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

13 Analysts have issued a MacroGenics, Inc. forecast:

7x Buy
54%
6x Hold
46%

Analyst Opinions

13 Analysts have issued a MacroGenics, Inc. forecast:

Buy
54%
Hold
46%

Financial data from MacroGenics, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
128 128
10% 10%
100%
- Direct Costs 32 32
356% 356%
25%
96 96
28% 28%
75%
- Selling and Administrative Expenses 58 58
5% 5%
46%
- Research and Development Expense 152 152
18% 18%
119%
-70 -70
29% 29%
-55%
- Depreciation and Amortization 7.52 7.52
2% 2%
6%
EBIT (Operating Income) EBIT -78 -78
27% 27%
-61%
Net Profit -75 -75
23% 23%
-59%

In millions USD.

Don't miss a Thing! We will send you all news about MacroGenics, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

MacroGenics, Inc. Stock News

Neutral
GlobeNewsWire
30 days ago
ROCKVILLE, MD, Nov. 25, 2025 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer, today announced that Eric Risser, President and CEO of MacroGenics, will participate in a fireside chat at the 8th Annual Evercore Healthcare Conference on Thursday, December 4, at 7:55 am ET in M...
Neutral
GlobeNewsWire
about one month ago
ROCKVILLE, Md., Nov. 12, 2025 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer, today reported financial results for the third quarter ended September 30, 2025, and provided an update on its recent corporate progress.
Neutral
GlobeNewsWire
about 2 months ago
ROCKVILLE, MD, Nov. 06, 2025 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer, today announced that Eric Risser, President and CEO of MacroGenics, will participate in a fireside chat at the Stifel 2025 Healthcare Conference on Thursday, November 13, 2025, at 4:00 pm ET in Ne...
More MacroGenics, Inc. News

Company Profile

MacroGenics, Inc. is a clinical-stage biopharmaceutical company, which engages in discovering and developing antibody-based therapeutics designed to modulate the human immune response for the treatment of cancer. 2. Its product pipeline includes Margetuximab, Flotetuzumab, Enoblituzumab, MGA012, MGD013, MGD019, MGD009, MGC018, and MGD007 for oncology; and MGD014 for infectious diseases. The company was founded by Scott E. Koenig, Jeffrey V. Ravetch, LeRoy E. Hood, Ruedi Aebersold, and Alan Aderem on August 14, 2000 and is headquartered in Rockville, MD.

Head office United States
CEO Scott Koenig
Employees 341
Founded 2000
Website www.macrogenics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today